Immunosuppressive agents in transplantation: Mechanisms of action and current anti-rejection strategies

Microsurgery

Volumn 20, Issue 8, 2000, Pages 420-429

  Gorantla, Vijay S ^a   Barker, John H ^a   Jones Jr , Jon W ^b   Prabhune, Kaustubha ^a   Maldonado, Claudio ^a   Granger, Darla K ^a  

^a University of Louisville School of Medicine   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOTRANSPLANTATION; COMPOSITE GRAFT; CONFERENCE PAPER; DRUG EFFICACY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; UNITED STATES;

DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0034502726     PISSN: 07381085     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2752(2000)20:8<420::AID-MICR13>3.0.CO;2-O     Document Type: Conference Paper

References (61)

1. The historical background of transplantation
2. Immunosuppressive drugs in renal transplantation: A review of the regimens
3. Cyclosporin A - Present experimental status
4. Selective conversion from azathioprine to cyclosporin for steroid-resistant rejection in renal transplants: An alternative therapy
5. Cyclosporine in cadaveric renal transplantation: Five-year follow-up results of the European Multicenter Trial
6. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years
7. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - A multicenter investigation in kidney transplant patients
8. Variable oral absorption of cyclosporine: A biopharmaceutical risk factor for chronic renal allograft rejection
9. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients
10. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation
11. The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double blind comparison in primary renal allograft recipients
12. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis
13. Tacrolimus vs Neoral in renal and renal/pancreas transplantation
14. Effects of a novel irnmunosuppressive agent, FK506 on human B-cell activation
15. Conversion of renal transplant recipients from cyclosporin to low-dose tacrolimus for refractory rejection
16. Comparative evaluation of tacrolimus (FK506) and cyclosporine A as immunosuppressive agents
17. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation
18. Prednisone withdrawal 14 days after liver transplantation with mycophenolate - A prospective trial of cyclosporine and tacrolimus
19. Increased incidence of insulin dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506)
20. Tacrolimus and cyclosporine efficacy in high-risk kidney transplantation
21. Cyclosporine, but not FK506 selectively induces renal and coronary artery smooth muscle contraction
22. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine
23. The immunosuppressant FK506 increases GAP-43 mRNA levels in axotomized sensory neurons
24. FK506 and the role of immunophilins in nerve regeneration
25. Muromonab-CD3 and antithymocyte globulin in renal transplantation
26. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection
27. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants
28. Administration of OKT3 as a two-hour infusion attenuates first dose toxic side effects
29. Humanized, non-mitogenic OKT3 antibody, huOKT3 gamma (Ala-Ala): Initial clinical experience
30. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation
31. Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: A comparison of two different rabbit-antithymocyte globulins
32. A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation
33. Relationship of rabbit ATG serum clearance rate to circulating T cell level, rejection onset, and survival in cardiac transplantation
34. Randomized clinical trial of ATG in cadaver allograft recipients: Importance of T-cell monitoring
35. Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors
36. Antithymocyte globulin in cadaver kidney transplantation: A randomized trial based on T-cell monitoring
37. Canadian clinical trial of antilymphocyte globulin in human cadaver renal transplantation
38. Reversal of acute renal allograft rejections with adjunctive ATG therapy
39. Use of ATG in treatment of steroid-resistant rejection
40. Metabolic basis for the actions of analogues of purines and pyrimidines
41. Inhibition of the rejection of renal homografts in dogs with Burroughs-Wellcome 322
42. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil
43. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years
44. Risk factors for chronic rejection in renal allograft recipients
45. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double blind, clinical studies in prevention of rejection
46. Mechanisms of glucocorticoid hormone action
47. New immunosuppressive drug combinations for mismatched related and cadaveric renal transplantation
48. Steroid therapy and surgery
49. Steroids, retinoids and wound healing
50. Effects of glucocorticoids on lymphocyte function
51. The effect of in-vivo T-helper and T-suppressor lymphocyte depletion on wound healing
52. Rapamycin (AY-22989), a new antifungal antibiotic: Taxonomy of the producing streptomycete and isolation of the active principle
53. CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin
54. Sirolimus-tacrolimus combination immunosuppression
55. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial
56. Immunosuppressive effects and safety of a sirolimus/ cyclosporine combination regimen for renal transplantation
57. Effects of cyclosporine, FK506, and rapamycin on graft vessel disease
58. Islet transplantation in seven patients with type-1 diabetes mellitus using a glucocorticoid free immunosuppressive regimen
59. Successful hand transplantation: One-year follow-up
60. Human hand allograft: Report on first 6 months
61. Allogeneic vascularized transplantation of human femoral diaphyses and total knee joints: First clinical experiences